Acomplia (Rimonabant) is a diet drug that works to block CB1 receptors in the endocannabinoid system of the brain, digestive system, fat tissue, muscles and liver. The endocannabinoid system has recently been discovered and is being studied to determine how it can help with weight loss as it is responsible for balance, energy, metabolizing sugar and fat and ultimately weight loss. The CB1 receptors play an important role in our consumption of sweet and fatty foods. When the CB1 receptors are over active they can cause increased appetite and cravings for sweet and fatty foods. Acomplia contains a chemical called Rimonabant that can block these receptors which is response curbs appetite and helps suppress a hunger response. According to continued studies it is also possible that Acomplia can increase the presence of good fats by diminishing triglycerides.
After several clinical studies, Acomplia was initially approved by markets in the United Kingdom and was projected to be released as a prescription drug in Denmark, Ireland, Sweden, Germany, Finland, Norway and 50 additional countries excluding the US. In 2006 Acomplia was being prescribed to patients that were classified as obese, having a BMI of 30 or over, or a BMI of 27 alongside serious obesity risk factors such as diabetes or hypertension. However, shortly after being released, in 2008 Acomplia was pulled from the markets after adverse side effects began occurring as early as in the first week of its use by patients.
Makers of the drug Acomplia, Sanofi-Aventis withheld side effects that linked the drug to depression and suicidal thoughts in clinical trials but they were quickly revealed as patients began experiencing them. Two years after being released the European Medicines Agency along with the Committee for Medical products for Human Use determined that the risks simply did not outweigh the potentially deadly side effects of the drug.
According to the results of several trials, Acomplia did prove to reduce more weight after its first year of use than those who did not take the drug. However, patients that were taking Acomplia, instead of the placebo wound up being more than twice as likely to have had symptoms of anxiety, depression, or thoughts of harming themselves or committing suicide. Other side effects include irritability, paranoia, insomnia, sleep disorders, memory loss, dizziness, hypoaesthesia, fatigue, asthenia, diarrhea, pruritus and excessive sweating.
If you are taking Acomplia, it is recommended that stop taking the drug, and seek medical attention if you are experiencing any adverse side effects. Acomplia, and other products containing Rimonabant are also marketed under the following names; SR141716, Bethin, Monaslim, Remonabent, Riobant, Zimulti, Riomont and Slimona.